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Pronostic of cardiogenic shock (CS) is severe and mortality is still more
than 50%.
Aim of the study: Prospective study of patients consecutively hospitalized
for a first CS due to cardiomyopathy (CM) with LV dysfunction and a 18-
month period of follow-up.
Inclusion criteria: CS is defined by systolic BP<80mmHg or hemody-
namic support with peripheral hypoperfusion. All patients had echocardio-
graphy, coronarography and biological evaluation (troponine and NTproBNP).
Regular follow-up was realized at 1, 3 and 6 months using echocardiography,
stress test with oxygen consumption and therapeutic adaptation (βblockers).
Exclusion criteria: acute coronary syndrome, septic, anaphylactic, hypov-
olemic shock.
Results: 24 patients (90% men) mean age 57,5±11,2 y were included; 8
ischemic CM, 15 dilated CM [11 idiopathic, 3 toxic (alcohol n=4 ; iatrogene
n=1), 1 myocarditis] et 1 restrictive CM (haemochromatose). Cardiovascular
risks were diabetes with HbA1c > 8% (n=11), HBP (n=7), tabacco (n=9), dys-
lipidemia (n=8). Upon admission NT proBNP value was 5025ng/mL and
1730ng/ml 8 weeks later. The mean LVEF was initially 23±8% and 39,5±13,7%
at the end of the follow up. The duration of hospitalisation was 12±15 days.
initial 6 mois 18 mois
NYHA IV Stage (%) 100 20 18
LBBB(%) 46 
Creatininemia (umol/l) 150 ± 100 130 ± 50 127 ± 42
LVEF% 24 ± 9% 30 ± 8% 39,5± 13,7
LVEDD (mm) 64±9 62 ± 10 61± 20,3
SPAP (mmHg) 50±14 49 ± 10 30 ± 9,4
NT pro BNP (ng/ml) 5025±8200 3800±6200 1730 ± 4200
At the end of the follow up, in 6 patients heart failure symptoms decreased
and 3 patients normalized their LVEF. 3 patients alone had a βblocker treat-
ment, 2 resynchronisations, and with DAI for 1 patient and 2 transplantations.
3 patients died due to cardiogenic complications (all with an ischemic cardi-
omyopathy) and 7 patients had iterative hospitalisation for heart failure.
Conclusion: The pronostic of cardiogenic shock without acute coronary
syndrome is better with the improvement of therapeutic methods but, in this
study the severity was important: death = 12.5%, morbidity = 31.2%. 
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Purpose: In healthy individuals, reducing inspired oxygen concentrations
to 15% (equivalent to an altitude of ~2500 metres or usual aircraft cabin pres-
sure) causes an increase in heart rate (HR), left ventricular ejection fraction
(LVEF) and pulmonary arterial pressure (PAP). The clinical and haemody-
namic responses to hypoxia (15% oxygen) have not been reported in patients
with chronic heart failure (CHF).
Methods: Patients with CHF were enrolled who met at least one of the fol-
lowing criteria: NYHA≥III, LVEF <40%, or diuretic dose equivalent to furo-
semide ≥ 80mg. Patients inspired 15% oxygen from a Douglas bag through a
mouthpiece whilst lying supine. Clinical and echocardiographic measurements
were performed at baseline and after one hour of hypoxia.
Results: Thirty two CHF patients (mean age and LVEF were 63±13yrs and
33±9% respectively) were recruited. 70% had ischemic heart disease and 22%
had permanent atrial fibrillation. Hypoxia was well tolerated and was not asso-
ciated with worsening HF-symptoms. Arterial oxygen saturation (SpO2)
decreased from 97.2±1.2 to 85.7±5.0%, p<0.0001. Mean systemic blood pres-
sure (MSBP) increased from 84±11mmHg to 92±11mmHg, p<0.0001, whilst
HR remained unchanged at 69±14bpm. LVEF and E/A ratio were unchanged.
Diastolic LV function tended to improved (E/Ea from 13.6±7.2 to 12.3±7.7
p=0.09). Systolic PAP increased (from 34±9mmHg to 38±9mmHg, p<0.05 in
n=16 patients with tricuspid regurgitation) and the right ventricular systolic
function assessed by the tricuspid annular systolic excursion was unchanged.
Conclusion: Hypoxia caused no symptoms in any patients despite a significant
increase in MSBP and a decrease in arterial SpO2. Further investigations in a
larger patient group and with longer periods of hypoxia are being conducted.
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Background: European Guidelines for the treatment of CHF 2008 under-
line that there is no absolute level of creatinine which precludes the use of
angiotensin converting enzyme inhibitors (ACE-Is) or angiotensin receptor
blocker (ARBs).
Aims: The IMPACT-RECO program III analysed the impact of NYHA
class and of comorbidities on therapeutic management of French outpatients
with stable CHF and low left ventricular ejection fraction (LVEF).
Methods: This survey was carried on 2007 among randomly selected
French private cardiologists. 1574 patients with CHF and LVEF < 40% were
included.
Results: Mean age was 71 ± 11 years, 75% of the patients were men, 34%
were in NYHA class III-IV, 54% had coronary artery diseases, 30% had atrial
fibrillation and the mean LVEF was 34 ± 7%. Creatinine value was recorded
in 1332 patients. Mean creatinine concentration was 119 ± 50 μmol/L and
mean creatinine clearance was 59.6 ± 26.8 ml/kg/min. Renal dysfunction
defined by creatinine concentration > 220 μmol/L or 25 mg/dL was found in
173 patients. In the 467 patients not receiving ACEIs, reasons for non pre-
scription were firstly contra-indication in 69 patients (14.8%) mostly because
of renal dysfunction in 54 patients (78.3%), secondly side effects in 365
patients (78.2%) with renal insufficiency found in 25 patients (6.85%). In 1033
patients, ARBs was also not prescribed because of contra-indication for renal
dysfunction in 79 patients (90.8%), or intolerance with renal insufficiency in
40 patients (32.8%). Thus, despite a mean creatinine clearance of 33.3 ± 15.1
mL/kg/min in 173 patients with renal dysfunction, ACEIs/ARB were not pre-
scribed in 133 patients considering renal dysfunction as a contra-indication.
Conclusion: Renal dysfunction remains the main reason for not prescribing
ACEIs/ARBs in CHF despite the possibility to easily adapt their dose to crea-
tinine clearance. Improvement is still necessary so that ACEIs/ARBs should
not be denied to CHF patients with concomitant renal dysfunction.
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